Last 47 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | 2.65 | 3.02 | 1.06 | — | — | — | — | 232.66 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 0.08 | 0.21 | 0.29 | 0.18 | 0.29 | 0.26 | 0.27 | 0.67 | 1.96 | 1.96 | 2.97 | 2.35 | 1.98 | 3.13 | 3.11 | 1.91 | 2.85 | 2.03 | 3.69 | 3.01 | 3.73 |
| — | -19.5% | +7.3% | -73.4% | -85.2% | -86.8% | -90.9% | -71.4% | -1.2% | -37.4% | -4.2% | +23.2% | -30.5% | +54.1% | -15.7% | -36.7% | -23.6% | -65.0% | +62.8% | -17.8% | +85.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | -48.1% | -22.9% | 65.5% | — | — | — | — | -34.4% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | -785.4% | -1931.0% | -228.7% | — | — | — | — | -7087.0% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | -593.3% | -1273.4% | -208.4% | — | — | — | — | -6920.1% | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -49.4% | -12.2% | -26.1% | -9.6% | -11.0% | -13.4% | -16.5% | -13.7% | -13.5% | -12.7% | -10.3% | -10.4% | -10.5% | -8.9% | -10.9% | -3.5% | -7.5% | -7.7% | -6.2% | -7.2% | -3.7% |
| — | +8.8% | -58.5% | +29.6% | +18.5% | -5.4% | -59.4% | -30.8% | -28.4% | -42.6% | +5.3% | -197.1% | -40.2% | -15.7% | -75.9% | +51.0% | -103.5% | -74.1% | -14.1% | +73.8% | +72.2% | |
| ROA | -30.2% | -6.5% | -15.6% | -6.1% | -6.2% | -7.1% | -9.0% | -8.2% | -10.1% | -11.3% | -9.1% | -9.2% | -9.3% | -7.9% | -9.7% | -3.2% | -6.8% | -7.1% | -5.7% | -6.6% | -3.4% |
| — | +8.6% | -72.6% | +26.4% | +39.0% | +37.3% | +0.8% | +10.4% | -8.6% | -42.5% | +6.8% | -188.4% | -36.2% | -11.2% | -71.7% | +51.7% | -98.7% | -71.5% | -17.1% | +68.0% | +65.8% | |
| ROIC | -39.5% | -13.4% | -31.6% | -8.3% | -9.1% | -10.3% | -12.7% | -10.8% | -11.9% | -11.7% | -12.4% | -10.7% | -11.6% | -10.1% | -12.5% | -8.6% | -9.0% | -10.6% | -9.2% | -11.2% | -9.0% |
| — | -29.9% | -147.8% | +23.2% | +22.9% | +11.8% | -3.2% | -1.1% | -2.3% | -15.8% | +1.3% | -25.2% | -28.4% | +4.7% | -35.3% | +24.0% | +0.2% | +45.7% | +32.1% | +59.6% | +37.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.09 | 0.01 | 0.02 | 0.02 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| — | +239.5% | -20.2% | +559.5% | +559.4% | +650.9% | +212.7% | -40.9% | -32.6% | -31.6% | -26.1% | -19.6% | -19.7% | -17.5% | -2.5% | -4.3% | +1.8% | -15.1% | -35.8% | -87.2% | -84.0% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 0.62 | 0.84 | 0.58 | 0.99 | 0.62 | 0.47 | 0.37 | 0.41 | 0.40 | 6.75 | 5.17 | 5.06 | 5.95 | 7.10 | 5.62 | 9.33 | 9.84 | 11.40 | 14.49 | 9.25 | 18.28 |
| — | +76.7% | +56.3% | +142.8% | +56.6% | -93.0% | -92.9% | -91.9% | -93.3% | -5.0% | -8.0% | -45.8% | -39.5% | -37.7% | -61.2% | +0.8% | -46.2% | -64.9% | -58.8% | +488.5% | +435.8% | |
| Quick Ratio | 0.13 | 0.40 | 0.16 | 0.40 | 0.13 | 0.14 | 0.06 | 0.09 | 0.17 | 6.75 | 5.17 | 5.06 | 5.95 | 7.10 | 5.62 | 9.33 | 9.84 | 11.40 | 14.49 | 9.25 | 18.28 |
| — | +180.8% | +169.6% | +354.9% | -24.3% | -97.9% | -98.8% | -98.3% | -97.2% | -5.0% | -8.0% | -45.8% | -39.5% | -37.7% | -61.2% | +0.8% | -46.2% | -64.9% | -58.8% | +488.5% | +435.8% | |
| Interest Coverage | -143.46 | -28.53 | -974.68 | -57.99 | -87.77 | -50.90 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying CTXR stock.
Citius Pharmaceuticals, Inc.'s current P/E is -0.2x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Citius Pharmaceuticals, Inc.'s business trajectory between earnings reports.